These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 13409866)

  • 1. [Effect of polymethylene-bis-(N-methyl-carbamic acid-m-trimethylammonium-phenol) BC 40, BC 47, BC 48 on cholinesterase activity and muscle activity in myasthenia gravis pseudoparalytica].
    PATEISKY K; HERZFELD E; STUMPF C
    Wien Klin Wochenschr; 1957 Jan; 69(1):2-7. PubMed ID: 13409866
    [No Abstract]   [Full Text] [Related]  

  • 2. [Treatment of myasthenia gravis pseudoparalytica; clinical testing and therapy with BC substances (BC40, BC47, BC48 and BC 51)].
    PATEISKY K
    Wien Z Nervenheilkd Grenzgeb; 1959; 17():53-84. PubMed ID: 14430812
    [No Abstract]   [Full Text] [Related]  

  • 3. [Clinical experiences with hexamethylenebis (N-methylcarbamoyl-m-trimethylammonium-phenol in pseudoparalytic myasthenia gravis].
    PATEISKY K; KRAUPP O; STUMPF C
    Wien Klin Wochenschr; 1955 Aug; 67(32):578-81. PubMed ID: 13257133
    [No Abstract]   [Full Text] [Related]  

  • 4. [Therapy of myasthenia gravis; clinical experiences with the treatment of myasthenia gravis pseudoparalytica with pyridostigmine].
    SEIBERT P
    Dtsch Med Wochenschr; 1953 May; 78(22):805-7. PubMed ID: 13067995
    [No Abstract]   [Full Text] [Related]  

  • 5. [Variations in permeability induced by decamethylene-bis-(N-methyl-carbamic acid-m-trimethylammoniumphenol) (BC 48)].
    PILLAT B; STUMPF C; GITTLER R; POMMER H
    Arch Int Pharmacodyn Ther; 1956 Dec; 108(3-4):481-7. PubMed ID: 13412182
    [No Abstract]   [Full Text] [Related]  

  • 6. [Studies on cholinesterase inhibiting effects of polymethylene-bis-(N-methyl-carbamic acid-m-trimethylammoniumphenols)].
    HERZFELD E; STUMPF C
    Arch Int Pharmacodyn Ther; 1956 Jul; 107(1):33-44. PubMed ID: 13341144
    [No Abstract]   [Full Text] [Related]  

  • 7. [Pharmacological and clinical effects of cholinesterase antagonist hexamethylene-bis(N-methylcarbaminoyl-1-methyl-3-oxypyridiniumbromide); (BC 51)].
    HERZFELD E; KRAUPP O; PATEISKY K; STUMPF C
    Wien Klin Wochenschr; 1957 Apr; 69(14):245-8. PubMed ID: 13443301
    [No Abstract]   [Full Text] [Related]  

  • 8. Cholinesterase inhibition and signs and symptoms in myasthenia gravis.
    WILSON A; MAW GA; GEOGHEGAN H
    Q J Med; 1951 Jan; 20(77):21-31. PubMed ID: 24540156
    [No Abstract]   [Full Text] [Related]  

  • 9. [Comparison of the cholinoreceptor and cholinesterase properties of the frog Rana temporaria and the squid Todarodes pacificus].
    Danilov AF; Viniar TN; Lavrent'eva VV; Rozengart EV
    Zh Evol Biokhim Fiziol; 1985; 21(2):139-43. PubMed ID: 3158137
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hydrolysis of neostigmine by plasma cholinesterase.
    NOWELL PT; SCOTT CA; WILSON A
    Br J Pharmacol Chemother; 1962 Dec; 19(3):498-502. PubMed ID: 13939168
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cholinesterase activity of blood and muscle in myasthenia gravis.
    WILSON A; MAW GA; GEOGHEGAN H
    Q J Med; 1951 Jan; 20(77):13-9. PubMed ID: 24540155
    [No Abstract]   [Full Text] [Related]  

  • 12. The effects of neostigmine on the response of the rat anococcygeus muscle to field stimulation are not a consequence of cholinesterase inhibition.
    Smith JA; Spriggs TL
    J Pharm Pharmacol; 1985 Jan; 37(1):49-52. PubMed ID: 2858527
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Myasthenia gravis. II. Histochemical demonstration of acetylcholinesterase activity in motor end-plates of extraocular muscle in patients with myasthenia gravis; a post-mortem study.
    COHEN RB; ZACKS SI
    Am J Pathol; 1959; 35(2):399-405. PubMed ID: 13627134
    [No Abstract]   [Full Text] [Related]  

  • 14. Prostigmine-induced muscle weakness in myasthenia gravis patients.
    ROWLAND LP; KORENGOLD MC; JAFFE IA; BERG L; SHY GM
    Neurology; 1955 Feb; 5(2):89-99. PubMed ID: 13235984
    [No Abstract]   [Full Text] [Related]  

  • 15. Grob on myasthenia gravis.
    KAHN A
    J Ark Med Soc; 1963 Jan; 59():317-8. PubMed ID: 13958281
    [No Abstract]   [Full Text] [Related]  

  • 16. Plasma neostigmine levels and cholinesterase inhibition in dogs and myasthenic patients.
    GOLDSTEIN A; KRAYER O
    J Pharmacol Exp Ther; 1949 May; 96(1):56-85. PubMed ID: 18150736
    [No Abstract]   [Full Text] [Related]  

  • 17. [Myasthenia gravis. I. The action of anti-cholinesterase drugs on normal human extraocular muscles].
    Sato Y
    Nippon Ganka Gakkai Zasshi; 1967 Jul; 71(7):989-99. PubMed ID: 5625259
    [No Abstract]   [Full Text] [Related]  

  • 18. [Myasthenia gravis pseudoparalytica in a seven year old child].
    SCHONFELDER T
    Arch Kinderheilkd; 1955; 150(2):180-4. PubMed ID: 14377487
    [No Abstract]   [Full Text] [Related]  

  • 19. [Treatment of myasthenia gravis pseudoparalytica].
    UNTERHARNSCHEIDT F
    Nervenarzt; 1955 Jul; 26(7):275-9. PubMed ID: 13265940
    [No Abstract]   [Full Text] [Related]  

  • 20. [A case of Erb-Goldflam myasthenia. Trial of a new anti-myasthenic product].
    SUTTER ; JORDA ; LEBASCLE
    Rev Otoneuroophtalmol; 1953 Apr; 25(3):169-72. PubMed ID: 13075453
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.